FROOME CLOSEMedical Technologies

Drug Calculator Health Economics Drug AE Drug Label Drug Sync← Main site

Froome Close

Medical Technologies

Overview Drug AE Drug Sync Drug Calculator Health Economics Contact froomeclose.com

© 2026 Froome Close. Clinical information is intended for use by qualified healthcare professionals only. Not a substitute for clinical judgement.

Health Economics — Froome Close

← Health Economics

Acute myeloid leukemia

Select a treatment setting

First-line/Induction

First-line induction therapy older or "unfit" patients1 biomarker

First-line induction therapy older patients or "unfit" patients2 biomarker

First-line induction therapy, older or "unfit" patients1 biomarker

IDH1 first-line therapy older or 'unfit' patients3 biomarker

IDH2 first-line therapy older or 'unfit' patients1 biomarker

Upfront induction therapy2 biomarker

Upfront induction therapy standard and older "fit" patients

Upfront induction therapy standard patients6 biomarker

Relapsed/Refractory/Later-line

Subsequent induction therapy standard and older "fit" patients

IDH1 relapsed or refractory2 biomarker

IDH2 Relapsed or refractory3 biomarker

Consolidation

Consolidation after salvage therapy

Consolidation after upfront therapy4 biomarker

Maintenance

Maintenance after allogeneic HSCT

Maintenance after first-line therapy

Maintenance after upfront therapy including allogeneic HSCT5 biomarker

3

With dosing

3

›

Relapsed or refractory further lines of therapy7 biomarker

Relapsed or refractory salvage therapy1 biomarker

Relapsed or refractory subsequent lines of therapy

3

›